Use of cannabinoids for the management of chronic cancer pain: Integrative review
DOI:
https://doi.org/10.33448/rsd-v11i17.38531Keywords:
Medical Marijuana; Cannabinoids; Chronic pain; Cannabis; Cancer pain.Abstract
Objective: To present publications expressed in the world scientific literature on the use of cannabinoids in the management of chronic cancer pain. Method: Integrative literature review whose data search was performed using the descriptors “Medical Marijuana”, “Cannabinoids”, “Cannabis”, “Chronic Pain”, “Cancer Pain”, defined from the vocabulary of Health Sciences Descriptors ( DeCS), these terminologies were combined using the Boolean operator AND in the electronic databases: Medical Literature Analysis and Retrieval System Online (MEDLINE) and Latin American and Caribbean Literature in Health Sciences (LILACS) via the Library Virtual Health (VHL). Scientific Electronic Library Online (SciELO), Web of Science (WOS), Cinahl and Scopus via CAPES Journal Portal and Cochrane Library. Results: A total of 208 studies were identified in these databases. With 40 in Medline, 01 in LILACS, 0 in SciELO, 89 in the Scopus database, 62 in the Web of Science, 9 in the Cochrane Library and 7 in CINAHL, 27 duplicate articles were excluded, leaving 181 articles. Of these, 117 articles that did not directly address the object of this research were excluded, resulting in a final sample of 10 articles. Conclusion: There is preclinical evidence that CBD can address several of the underlying pathways of cancer, and there is preclinical and clinical evidence that CBD can be effective in treating many of the symptoms and signs associated with the disease and its orthodox treatment. , however, studies that address: administration, dosage schedules and absorption of medical cannabis in the treatment of cancer are still scarce in the literature.
References
Abrams D. I. (2019). Should Oncologists Recommend Cannabis?. Current treatment options in oncology, 20(7), 59. https://doi.org/10.1007/s11864-019-0659-9
Bass, J., & Linz, D. R. (2020). A Case of Toxicity from Cannabidiol Gummy Ingestion. Cureus, 12(4), e7688. https://doi.org/10.7759/cureus.7688
Beaulieu, P., Boulanger, A., Desroches, J., & Clark, A. J. (2016). Medical cannabis: considerations for the anesthesiologist and pain physician. Canadian journal of anaesthesia = Journal canadien d'anesthesie, 63(5), 608–624. https://doi.org/10.1007/s12630-016-0598-x
Bhaskar, A., Bell, A., Boivin, M., Briques, W., Brown, M., Clarke, H., Cyr, C., Eisenberg, E., de Oliveira Silva, R. F., Frohlich, E., Georgius, P., Hogg, M., Horsted, T. I., MacCallum, C. A., Müller-Vahl, K. R., O'Connell, C., Sealey, R., Seibolt, M., Sihota, A., Smith, B. K., … Moulin, D. E. (2021). Consensus recommendations on dosing and administration of medical cannabis to treat chronic pain: results of a modified Delphi process. Journal of cannabis research, 3(1), 22. https://doi.org/10.1186/s42238-021-00073-1
Black, N., Stockings, E., Campbell, G., Tran, L. T., Zagic, D., Hall, W. D., Farrell, M., & Degenhardt, L. (2019). Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis. The lancet. Psychiatry, 6(12), 995–1010. https://doi.org/10.1016/S2215-0366(19)30401-8
Bruce, D., Brady, J. P., Foster, E., & Shattell, M. (2018). Preferences for Medical Marijuana over Prescription Medications Among Persons Living with Chronic Conditions: Alternative, Complementary, and Tapering Uses. Journal of alternative and complementary medicine (New York, N.Y.), 24(2), 146–153. https://doi.org/10.1089/acm.2017.0184
Chapman, E. J., Edwards, Z., Boland, J. W., Maddocks, M., Fettes, L., Malia, C., Mulvey, M. R., & Bennett, M. I. (2020). Practice review: Evidence-based and effective management of pain in patients with advanced cancer. Palliative medicine, 34(4), 444–453. https://doi.org/10.1177/0269216319896955
Darkovska-Serafimovska, M., Serafimovska, T., Arsova-Sarafinovska, Z., Stefanoski, S., Keskovski, Z., & Balkanov, T. (2018). Pharmacotherapeutic considerations for use of cannabinoids to relieve pain in patients with malignant diseases. Journal of pain research, 11, 837–842. https://doi.org/10.2147/JPR.S160556
Datta, S., Ramamurthy, P. C., Anand, U., Singh, S., Singh, A., Dhanjal, D. S., Dhaka, V., Kumar, S., Kapoor, D., Nandy, S., Kumar, M., Koshy, E. P., Dey, A., Proćków, J., & Singh, J. (2021). Wonder or evil?: Multifaceted health hazards and health benefits of Cannabis sativa and its phytochemicals. Saudi journal of biological sciences, 28(12), 7290–7313. https://doi.org/10.1016/j.sjbs.2021.08.036
Davis M. P. (2016). Cannabinoids for Symptom Management and Cancer Therapy: The Evidence. Journal of the National Comprehensive Cancer Network : JNCCN, 14(7), 915–922. https://doi.org/10.6004/jnccn.2016.0094
Eadie, L., Lo, L. A., Christiansen, A., Brubacher, J. R., Barr, A. M., Panenka, W. J., & MacCallum, C. A. (2021). Duration of Neurocognitive Impairment With Medical Cannabis Use: A Scoping Review. Frontiers in psychiatry, 12, 638962. https://doi.org/10.3389/fpsyt.2021.638962
Fanelli, G., De Carolis, G., Leonardi, C., Longobardi, A., Sarli, E., Allegri, M., & Schatman, M. E. (2017). Cannabis and intractable chronic pain: an explorative retrospective analysis of Italian cohort of 614 patients. Journal of pain research, 10, 1217–1224. https://doi.org/10.2147/JPR.S132814
Graczyk, M., Łukowicz, M., & Dzierzanowski, T. (2021). Prospects for the Use of Cannabinoids in Psychiatric Disorders. Frontiers in psychiatry, 12, 620073. https://doi.org/10.3389/fpsyt.2021.620073
Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA). (2020). Estimativa 2020: Incidência de câncer no Brasil. Rio de Janeiro, https://www.inca.gov.br/sites/ufu.sti.inca.local/files//media/document//estimativa-2020-incidencia-de-cancer-no-brasil.pdf
Jugl, S., Okpeku, A., Costales, B., Morris, E. J., Alipour-Haris, G., Hincapie-Castillo, J. M., Stetten, N. E., Sajdeya, R., Keshwani, S., Joseph, V., Zhang, Y., Shen, Y., Adkins, L., Winterstein, A. G., & Goodin, A. (2021). A Mapping Literature Review of Medical Cannabis Clinical Outcomes and Quality of Evidence in Approved Conditions in the USA from 2016 to 2019. Medical cannabis and cannabinoids, 4(1), 21–42. https://doi.org/10.1159/000515069
Lakha, S. F., Deshpande, A., Assimakopoulos, D., & Mailis, A. (2021). Demographics, Pain Characteristics and Diagnostic Classification Profile of Chronic Non-Cancer Pain Patients Attending a Canadian University-Affiliated Community Pain Clinic. Pain and therapy, 10(2), 1413–1426. https://doi.org/10.1007/s40122-021-00301-9
Lichtman, A. H., Lux, E. A., McQuade, R., Rossetti, S., Sanchez, R., Sun, W., Wright, S., Kornyeyeva, E., & Fallon, M. T. (2018). Results of a Double-Blind, Randomized, Placebo-Controlled Study of Nabiximols Oromucosal Spray as an Adjunctive Therapy in Advanced Cancer Patients with Chronic Uncontrolled Pain. Journal of pain and symptom management, 55(2), 179–188.e1. https://doi.org/10.1016/j.jpainsymman.2017.09.001
Lynch, M. E., Young, J., & Clark, A. J. (2006). A case series of patients using medicinal marihuana for management of chronic pain under the Canadian Marihuana Medical Access Regulations. Journal of pain and symptom management, 32(5), 497–501. https://doi.org/10.1016/j.jpainsymman.2006.05.016
Maida, V., & Daeninck, P. J. (2016). A user's guide to cannabinoid therapies in oncology. Current oncology (Toronto, Ont.), 23(6), 398–406. https://doi.org/10.3747/co.23.3487
Makki, I., Zheng-Lin, B., & Kohli, M. (2022). Medical marijuana knowledge and attitudes amongst internal medicine residents. BMC primary care, 23(1), 38. https://doi.org/10.1186/s12875-022-01651-9
Ministério da Saúde. Secretaria de Ciência Inovação e Insumos Estratégicos em Saúde. Coordenação de Monitoramento e Avaliação de Tecnologias em Saúde T. (2021a). Opioides fortes (fentanila, oxicodona e buprenorfina) para o tratamento de dor crônica TT - Strong opioids (fentanyl, oxycodone and buprenorphine) for the treatment of chronic pain. https://fi-admin.bvsalud.org/document/view/p5k8h
Ministério da Saúde. Secretaria de Ciência Inovação e Insumos Estratégicos em Saúde. Coordenação de Monitoramento e Avaliação de Tecnologias em Saúde T.(2021c). Pregabalina para o tratamento de dor neuropática e fibromialgia TT - Pregabalin for Pain Treatment neuropathic and fibromyalgia. https://fi-admin.bvsalud.org/document/view/wrwe6
Ministério da Saúde. Secretaria de Ciência Inovação e Insumos Estratégicos em Saúde. Coordenação de Monitoramento e Avaliação de Tecnologias em Saúde T (2021b). Tramadol para o tratamento da dor crônica TT - Tramadol for the treatment of chronic pai., https://fi-admin.bvsalud.org/document/view/mhpdf
Mücke, M., Weier, M., Carter, C., Copeland, J., Degenhardt, L., Cuhls, H., Radbruch, L., Häuser, W., & Conrad, R. (2018). Systematic review and meta-analysis of cannabinoids in palliative medicine. Journal of cachexia, sarcopenia and muscle, 9(2), 220–234. https://doi.org/10.1002/jcsm.12273
Murnion B. (2015). Medicinal cannabis. Australian prescriber, 38(6), 212–215. https://doi.org/10.18773/austprescr.2015.072
Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., Chou, R., Glanville, J., Grimshaw, J. M., Hróbjartsson, A., Lalu, M. M., Li, T., Loder, E. W., Mayo-Wilson, E., McDonald, S., McGuinness, L. A., … Moher, D. (2021). The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Systematic reviews, 10(1), 89. https://doi.org/10.1186/s13643-021-01626-4
Simonian, J. S., Varanasi, S., Richards, G. J., Van Nguyen, A., Diaz-Fong, J. P., & Le, J. (2020). A critical narrative review of medical cannabis in pediatrics beyond epilepsy, part III: chemotherapy-induced nausea and vomiting and inflammatory bowel disease. Pediatric Medicine, 3. https://doi: 10.21037/pm-20-70
Verma, R., Hoda, F., Arshad, M., Iqubal, A., Siddiqui, A. N., Khan, M. A., Haque, S. E., Akhtar, M., & Najmi, A. K. (2021). Cannabis, a Miracle Drug with Polyvalent Therapeutic Utility: Preclinical and Clinical-Based Evidence. Medical cannabis and cannabinoids, 4(1), 43–60. https://doi.org/10.1159/000515042
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Luiz Otávio Pereira Santos; Amanda Rodrigues Rehem; Leandro Andrade da Silva; Liliana Scorzoni
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
